Are Hedge Funds Buying TELL, LGCY, AROC, and CLB?

13F filings: hedge funds statistics

In this part, we’ll take a look at how hedge funds are positioning themselves in the leading gainers and decliners from the upstream and oilfield services sectors of the current week.

Are Hedge Funds Buying TELL, LGCY, AROC, and CLB?

Tellurian

In Q1 2018, ten hedge funds either created new positions or added to their positions in Tellurian (TELL). In the same quarter, 14 hedge funds were “sellers,” either closing their entire position or reducing existing positions of TELL stock. That means, in Q1 2018, total selling hedge funds outnumbered total buying hedge funds by four. As of March 31, 16 hedge funds that filed the 13F form held TELL in their portfolio, but no hedge funds had TELL in their top ten holdings.

Even when looked at from the aggregate number of shares point of view, for Q1 2018, 13F filing hedge funds decreased their aggregate TELL holdings by 43.5%, or from ~5.8 million shares to ~3.3 million shares.

Hedge funds statistics for LGCY, AROC, and CLB

Just like TELL, hedge funds also sold Legacy Reserves (LGCY). In Q1 2018, hedge funds decreased their aggregate holdings in LGCY by 32.1%.

Contrary to TELL and LGCY, in Q1 2018, hedge funds increased their aggregate holdings in Archrock (AROC) and Core Laboratories (CLB) by 55.1% and 8.0%, respectively.

Form 13F is an SEC mandate that must be submitted by all hedge funds that manage over $100 million in assets. These hedge funds have access to in-depth research and greater capital. Typically, when institutional investors buy a stock, it is a good sign that the stock could do well.